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Despite improvements in surgical techniques, local residual tumour micro-infiltration and circulating tumour cells continue to cause tumour recurrence after resection1–3. 
Furthermore, perioperative trauma-associated inflammation can 
promote tumour recurrence by accelerating local growth or tumour 
spread4–7. Chemotherapy and radiotherapy are often used after sur-
gery to prevent both local and metastatic tumour recurrence, but 
these therapies often cause toxicities8. More recently, immunother-
apy has been considered to inhibit cancer recurrence and metastasis 
effectively9–13.
Macrophages are cellular components of the innate immunity 
that phagocytize foreign substances and present them to T lym-
phocytes (T cells) without requiring specific ‘self-signal’ proteins 
expressed on the cell surface14–16. However, cancer cells can escape 
macrophage recognition via upregulation of the integrin-associated 
protein (IAP)—CD47—which provides the antiphagocytic ‘don’t 
eat me’ signal17–19. Blocking the interaction of CD47 with its ligand, 
signal regulatory protein-α (SIRPα ), which is expressed on macro-
phages, dendritic cells and neutrophils20, activates phagocytic cells 
and promotes their capacity to phagocytize cancer cells. At least 
three CD47 antagonists are currently being tested in clinical stud-
ies, but the occurrence of anaemia and thrombocytopenia caused by 
systemic administration of these antagonists remains a concern21–24. 
Efforts to avoid these severe side effects are essential to make CD47-
blocking immunotherapies clinically applicable.
Tumour-associated macrophages (TAMs) account for a sub-
stantial fraction of tumour-infiltrating immune cells25,26. TAMs dif-
ferentiate into separate functional phenotypes, denoted classically 
activated macrophages (the M1-like phenotype) and alternatively 
activated macrophages (the M2-like phenotype)27. The M1-like 
TAMs overexpress major histocompatibility complex class I and 
class II molecules, which play critical roles in antigen presentation. 
Conversely, M2-like TAMs exert pro-tumorigenic activities28,29 and 
respond to different tumour determining factors, in particular low 
pH values30. Infiltration of M2-like TAMs frequently correlates with 
tumour invasion, metastases, angiogenesis, T cell suppression and 
poor clinical outcome31–33. Thus, targeting M2-like TAMs could be 
critical to alter the tumour microenvironment (TME) into a more 
permissive environment for the function of immune cells.
In this Article we report a sprayed bioresponsive immunothera-
peutic fibrin gel that has been engineered to inhibit local tumour 
recurrence after surgery and development of distant tumours. The 
fibrin gel is a US Food and Drug Administration approved mate-
rial, and is formed by the interaction of fibrinogen and thrombin. 
We leverage the unique merits of fibrin gel here, including excellent 
biocompatibility, a convenient sprayable administration method for 
post-surgical treatment, and the ability to promote wound healing 
by creating a temporary shield to connect and protect injured tis-
sue34. Biocompatible CaCO3 nanoparticles are incorporated into the 
fibrin gel to serve as a release reservoir of immunomodulatory ther-
apeutics as well as a proton scavenger to modulate the acidity of the 
tumour environment35,36. The fibrinogen solution containing anti-
CD47 antibody-loaded CaCO3 nanoparticles (aCD47@CaCO3) and 
thrombin solution can be quickly sprayed and mixed within the 
tumour resection cavity after surgery to form an immunotherapeu-
tic fibrin gel in situ (Fig. 1a). We demonstrate that CaCO3 nanopar-
ticles can gradually dissolve and release the encapsulated aCD47 
in the acidic and inflamed TME, thus promoting the activation of 
M1-type TAMs, inducing macrophage phagocytosis of cancer cells 
via blockade of the CD47 and SIRPα interaction as well as boosting 
In situ sprayed bioresponsive immunotherapeutic 
gel for post-surgical cancer treatment
Qian Chen1,2,3, Chao Wang3, Xudong Zhang1,2, Guojun Chen1,2, Quanyin Hu1,2,3, Hongjun Li4, 
Jinqiang Wang3, Di Wen1,2, Yuqi Zhang3, Yifei Lu3,5, Guang Yang1,2, Chen Jiang5, Jun Wang4, 
Gianpietro Dotti6 and Zhen Gu   1,2,3,7,8*
Cancer recurrence after surgical resection remains a significant cause of treatment failure. Here, we have developed an in situ 
formed immunotherapeutic bioresponsive gel that controls both local tumour recurrence after surgery and development of dis-
tant tumours. Briefly, calcium carbonate nanoparticles pre-loaded with the anti-CD47 antibody are encapsulated in the fibrin 
gel and scavenge H+ in the surgical wound, allowing polarization of tumour-associated macrophages to the M1-like phenotype. 
The released anti-CD47 antibody blocks the ‘don’t eat me’ signal in cancer cells, thereby increasing phagocytosis of cancer 
cells by macrophages. Macrophages can promote effective antigen presentation and initiate T cell mediated immune responses 
that control tumour growth. Our findings indicate that the immunotherapeutic fibrin gel ‘awakens’ the host innate and adaptive 













































































































Fig. 1 | Schematic and characterization of the in situ formed immunotherapeutic fibrin gel. a, Schematic showing the in situ sprayed bioresponsive fibrin gel 
containing aCD47@CaCO3 nanoparticles within the post-surgery tumour bed. aCD47@CaCO3 nanoparticles encapsulated in fibrin scavenge H+ in the surgical 
wound site and release aCD47, thus promoting both polarization of TAMs to an M1-like phenotype and blockade of the ‘don’t eat me’ signal in cancer cells. 
b, Transmission electron microscopy (TEM) image of aCD47@CaCO3 nanoparticles. Scale bar, 100 nm. Experiments were repeated three times; a representative 
image is shown. c, Respresentative scanning TEM images of aCD47@CaCO3 nanoparticles showing the calcium (green), oxygen (red) and gadolinium 
labelled aCD47 (blue). Experiments were repeated three times. d, Average hydrodynamic size of aCD47@CaCO3 nanoparticles determined by dynamic light 
scattering. e,f, Representative cryo-scanning electron microscope (SEM) images of fibrin gel loaded with aCD47@CaCO3 nanoparticles. Scale bars, 1 μ m. 
Experiments were repeated three times. g, Representative fluorescent images of a cryosection of fibrin gel, in which fibrinogen was labelled with FITC, CaCO3 
nanoparticles with Cy5.5 (Cy5.5-labelled PEG-b-P(Glu) copolymers), and aCD47 was stained with rhodamine-conjugated anti-rat IgG antibody. Scale bar, 
10 μ m. Experiments were repeated three times. h, Cumulative release profiles of aCD47 from fibrin in solutions at different pH values. Data are presented as 
mean ±  s.e.m. (n =  3). i, Fluorescence IVIS imaging depicting the in vivo retention of aCD47–Cy5.5, 6 days after delivery of antibodies in different formulations. 
Experiments were repeated three times. j, Quantification of the in vivo retention profile of aCD47–Cy5.5. FL, fluorescence; a.u., arbitrary unit. Data are 
presented as mean ±  s.e.m. (n =  3). Statistical significance was calculated via one-way analysis of variance (ANOVA) with a Tukey post-hoc test. *P <  0.05.
antitumour T cell responses, while reducing the toxic effects associ-
ated with the systemic administration of aCD47.
In situ formation of fibrin gel by spray
aCD47@CaCO3 nanoparticles with a loading capacity of 5% and 
encapsulation efficiency of 50% were prepared by precipitation of 
Ca2+ and CO32− in a solution containing poly(ethylene glycol)-b-
poly(glutamic acid) (PEG-b-P(Glu)) block copolymers according to 
the methods in a previous study37. Monodisperse aCD47@CaCO3 
nanoparticles with a –diameter of ~100 nm were obtained, the size 
of which was controlled by the P(Glu) block through the interac-
















































































































































































































































































































































































































































Fig. 2 | Incorporation of CaCo3@fibrin for relieving immunosuppressive tMe.  B16F10 tumours were collected from mice 5 days after treatment.  
a,b, Representative flow cytometric analysis images (a) and the relative quantification of M2-like macrophages (CD206hi) and M1-like macrophages (CD80hi) 
gating on F4/80+CD11b+CD45+ cells (b). Data are presented as mean ± s.e.m. (n =  4). c, Secretion levels of IL-10 and IL-12p70 in different tumours. Data are 
presented as mean ±  s.e.m. (n =  5). d, Representative flow cytometric analysis images (left) and relative quantification (right) of CD45+ cells. Data are presented 
as mean ±  s.e.m. (n =  4). e, Representative flow cytometric analysis images (left) and relative quantification (right) of MDSCs (CD11b+Gr-1+) gating on CD45+ 
cells. Data are presented as mean ±  s.e.m. (n =  4). f, Representative flow cytometric analysis images (left) and relative quantification (right) of CD4+Foxp3+ T 
cells gating on CD3+CD4+ cells. Data are presented as mean ±  s.e.m. (n =  4). g, HIF1-α protein expression levels in B16F10 tumours analysed by western blotting. 
Experiments were repeated three times. h, Systemic IFN-γ and TNF-α levels before and after CaCO3@fibrin treatment (n =  7). i, Representative flow cytometric 
analysis gating on CD3+ cells (left) and absolute quantification (right) of CD8+ and CD4+ T cells in the tumour. Data are presented as mean ±  s.e.m. (n =  4). 
Statistical significance was calculated via one-way ANOVA with a Tukey post-hoc test (b,c,d–f,i) or Student’s t-test (h). *P <  0.05; **P <  0.01; ***P <  0.001.
further aggregation and agglomeration(Fig. 1b–d). Elemental map-
ping images (Fig. 1c) indicated the homogeneous distribution of 
aCD47 (gadolinium-chelated) in the CaCO3 nanoparticles.
Fibrin gel was quickly formed by simultaneously spraying and 
mixing equal volumes of solutions containing either fibrinogen 
with size-optimized aCD47@CaCO3 nanoparticles or thrombin, 
which was validated by a rheology test (Supplementary Fig. 1). 
Ca2+ associated with CaCO3 nanoparticles in the solution facili-
tates the formation of fibrin gel38. The mixture of the two solutions 
resulted in a rapid increase in the elastic modulus (G′). The mor-
phology of the fibrin gel containing aCD47@CaCO3 nanoparticles 
was observed using cryo-scanning electron microscopy (cryo-
SEM) imaging (Fig. 1e,f). To further substantiate the distribu-
tion of aCD47@CaCO3 nanoparticles in the hydrogel, fluorescein 
(FITC)-labelled fibrinogen and Cy5.5-labelled CaCO3 nanopar-
ticles were used for hydrogel formation. Frozen sections were 
stained with rhodamine-conjugated donkey anti-rat IgG antibody 
to detect the aCD47. As demonstrated by confocal imaging, the 
Cy5.5 signals from CaCO3 exhibited a uniform distribution pat-
tern in the gel and were co-localized with aCD47, further indi-
cating the encapsulation of aCD47 in the CaCO3 nanoparticles 
(Fig. 1g). The biodegradation behaviour of the Cy5.5-labelled 
fibrin gel was monitored using a fluorescence in vivo imaging 



























































































































































































































Fig. 3 | CD47 blockade for increasing phagocytosis in vitro and exerting antitumour immune responses in vivo. a, Representative confocal images of 
phagocytosis assays, in which B16F10 cancer cells were labelled with CellTracker DeepRed (red) and bone-marrow-derived macrophage cells (BMDMs) 
were labelled with CellTracker Green (green). Scale bar, 50 μ m. Experiments were repeated three times. b, Representative flow cytometric analysis 
images (left) and relative quantification (right) of the phagocytosis of cancer cells by BMDMs. Data are presented as mean ±  s.e.m. (n =  3). Phagocytosis 
or phagocytized cancer cells were quantified as the percentage of double-positive BMDMs among CellTracker Green-positive BMDMs or CellTracker 
DeepRed-cancer cells. c,d, Representative flow cytometric analysis images (c) and relative quantification of Ly6ChiLy6G− macrophages gating on CD45+ 
cells and the absolute percentage of CD11c+ cells in the tumour (d). Experiments were repeated three times. Data are presented as mean ±  s.e.m. (n =  4). 
e,f, Representative flow cytometric analysis images (e) and relative quantification of CD80+CD86+ dendritic cells and CD103+ dendritic cells gating on 
CD45+CD11c+ cells (f). Data are presented as mean ±  s.e.m. (n =  4). Statistical significance was calculated via two-tailed Student’s t-test (b) or one-way 
ANOVA with a Tukey post-hoc test (d,f). *P <  0.05; **P <  0.01; ***P <  0.001.
from the gel was undetectable, indicating degradation of the gel 
(Supplementary Fig. 2).
The CaCO3 nanoparticles dissolved and released the encapsu-
lated aCD47 by reacting with H+ in the acidic buffer (Supplementary 
Figs. 3 and 4). Meanwhile, CaCO3 nanoparticles elevated the pH 
values of the acidic solution as a proton scavenger (Supplementary 
Fig. 5). Encapsulation of aCD47@CaCO3 nanoparticles in the 
hydrogel allowed a gradual release of aCD47 (Fig. 1h). To evaluate 
the release behaviour in vivo, aCD47 was either dispersed in phos-
phate buffered saline (PBS), encapsulated in CaCO3 nanoparticles or 
in CaCO3@fibrin gel, and then injected or sprayed into the tumour 
resection cavity. The Cy5.5-labelled aCD47 signal was monitored 
and quantified by an IVIS (Fig. 1i,j and Supplementary Fig. 6). 
While 80% of the signal from the injected antibody in solution was 
undetectable at the resection site, 79% of aCD47 released from the 
CaCO3@fibrin gel remained detectable. The sustained release of 
aCD47 was further substantiated by confocal imaging of residual 
tumour sections, in which a remarkable fluorescence signal associ-
ated with the antibodies was observed away from the nanoparticles’ 
signal, indicating degradation of the CaCO3 nanoparticles and sus-
tained release of antibodies from the nanoparticles (Supplementary 
Fig. 7). Although the sustained release of therapeutics from the gel–
nanoparticle reservoir is advantageous compared with free cargo, 
the release kinetics for this application could be further optimized 
to maximize the therapeutic effects and minimize toxicities.
Immune response induced by CaCo3 and aCD47
Glycolytic metabolism of cancer cells in the hypoxic TME leads to 
the production of lactate and H+ (pH 6.5–6.8), both of which impair 
the functions of immune cells39. Local acidification (pH 6.0–7.0) is 
also observed in inflamed and injured tissues36. Considering the 
ability of CaCO3 to scavenge H+, we examined the immune effects 
caused by spreading of the CaCO3@fibrin gel (1 mg CaCO3 per 
mouse) within the tumour resection cavity. We observed a reduc-
tion of M2-like TAMs (CD206hiCD11b+F4/80+) and an increase of 
M1-like TAMs (CD80hiCD11b+F4/80+) (Fig. 2a,b)40,41. This polar-
ization was further confirmed by the reduced level of IL-10 (the pre-
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Fig. 4 | aCD47@CaCo3@fibrin for reducing recurrence of B16F10 tumours after surgery. a, In vivo bioluminescence imaging of B16F10 tumours after 
removal of the primary tumour. Four representative mice per treatment group are shown. Images associated with day 10 were taken before surgery. 
Experiments were repeated three times. b,c, Individual (b) and average (c) tumour growth kinetics in different groups. Growth curves were stopped when 
the first mouse of the corresponding group died. Data are presented as mean ±  s.e.m. (n =  8 for the aCD47@CaCO3@fibrin-treated group, n =  6 for the 
other groups). Statistical significance was calculated via one-way ANOVA with a Tukey post-hoc test for multiple comparisons. d, Survival corresponding 
to the tumour size of mice after different treatments as indicated (n =  8 for the aCD47@CaCO3@fibrin-treated group, n =  6 for the other groups). 
Statistical significance was calculated via the log-rank (Mantel–Cox) test. e, Weight changes of mice in different groups. Data are presented as mean ± 
s.e.m. (n =  8 for the aCD47@CaCO3@fibrin-treated group, n =  6 for the other groups). *P <  0.05, ***P <  0.001.
level of interleukin-12 (IL-12, the predominant cytokine secreted by 
M1 macrophages) in the TME (Fig. 2c). The observed polarization 
of macrophages to the M1 phenotype could be ascribed to mod-
ulation of the acidity of the TME, which usually favours M2-like 
macrophage polarization40. Compared to small molecules that 
promote M1-like macrophage polarization42, the CaCO3 scaveng-
ing of H+ within the inflamed tumour resection provides a simple 
approach. A correlation was observed between the concentration 
of CaCO3 nanoparticles and macrophage polarization, as assessed 
by flow cytometry (Supplementary Fig. 8). After CaCO3@fibrin 
treatment, reduction of myeloid-derived suppressor cells (MDSCs) 
and regulatory T cells (Tregs) and reduced expression of hypoxia-
inducible factor 1-ɑ (HIF1-ɑ) in the TME were also observed 
(Fig. 2d–g and Supplementary Fig. 9). Remarkably, CaCO3@
fibrin treatment caused an increase in tumour-infiltrating lym-
phocytes (TILs, CD3+), especially cytotoxic T lymphocytes (CTLs, 
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Fig. 5 | aCD47@CaCo3@fibrin for triggering antitumour immune response. B16F10 tumours were harvested from mice 5 days after treatment.  
a, Representative flow cytometric analysis images (left) and relative quantification (right) of M2-like macrophages (CD206hi) and M1-like macrophages 
(CD80hi) gating on F4/80+CD11b+CD45+ cells. Data are presented as mean ±  s.e.m. (n =  4). b, Representative flow cytometric analysis of T cell infiltration 
within the tumour gating on CD3+ cells (left) and the quantification results (right) in different groups. Data are presented as mean ±  s.e.m. (n =  4).  
c,d, Absolute percentage of the CD8+ (c) and CD4+ (d) T cells within tumours following various treatments. Data are presented as mean ±  s.e.m. (n =  4).  
e, Representative immunofluorescence images of tumours showing CD8+ T cell and F4/80+ macrophage infiltration for untreated and aCD47@CaCO3@fibrin 
groups. Scale bars, 50 μ m. Experiments were repeated three times. f, Cytokine levels in the serum from mice isolated 5 days after different treatments.  
Data are presented as mean ±  s.e.m. (n =  4). G1, untreated; G2, fibrin; G3, IgG@CaCO3@fibrin; G4, aCD47@fibrin; G5, aCD47@CaCO3@fibrin.  
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Fig. 6 | Local treatment of aCD47@CaCo3@fibrin for systemic antitumour immune response. a, Schematic illustrating aCD47@CaCO3@fibrin therapy in a 
mouse model of incomplete tumour resection and distant tumour. Tumours on the right side were designated as ‘primary tumours’ with aCD47@CaCO3@
fibrin treatment, and those on the left side were designated as ‘distant tumours’ without any treatment. b, In vivo bioluminescence imaging of B16F10 
tumours in response to local aCD47@CaCO3@fibrin treatment. Images associated with day 10 were taken before surgery. Experiments were repeated 
three times. c, Growth curves for left and right tumours in untreated and treated mice. Data are presented as mean ±  s.e.m. (n =  8). d, Representative mice 
photographs at day 22. Blue arrows indicate tumours. Experiments were repeated three times. e, Representative flow cytometric analysis images (left)  
and relative quantification (right) of M1-like macrophages (CD80hi) gating on F4/80+CD11b+CD45+ cells. Data are presented as mean ±  s.e.m. (n =  5).  
f, Representative flow cytometric analysis images (left) and relative quantification (right) of CD103+ dendritic cells gating on CD45+CD11c+ cells. Data are 
presented as mean ±  s.e.m. (n =  5). g, Representative flow cytometric analysis of T cell infiltration gating on CD3+ cells within the tumour (left) and the 
absolute percentage (right) of CD8+ T cells in the tumour in different groups. Data are presented as mean ±  s.e.m. (n =  5). Experiments were repeated three 
times. Statistical significance was calculated via one-way ANOVA with a Tukey post-hoc test. *P <  0.05; **P <  0.01; ***P <  0.001.
CD3+CD8+), within the tumour (Fig. 2i), as well as an increase 
in interferon-γ (IFN-γ ) and tumour necrosis factor-α (TNF-α ) in 
the plasma (Fig. 2h). Meanwhile, the expression of programmed 
death-1 (PD-1) protein and programmed death-ligand 1 (PD-L1) 
on immune cells and cancer cells, respectively, remained nearly 
unchanged or slightly decreased (Supplementary Fig. 10).
CD47 blockade increased the phagocytosis of cancer cells by 
macrophages in vitro, as shown in the confocal imaging and flow 
cytometry results (Fig. 3a,b and Supplementary Fig. 11). When 
aCD47 was loaded into the fibrin gel (50 μ g aCD47 per mouse) 
and sprayed at the tumour resection site, an increased frequency 
of Ly6ChiLy6G− macrophages within the resection tumour cavity 
was observed, but not for Ly6G+Ly6Cdim neutrophils (Fig. 3c,d and 
Supplementary Fig. 12). An increase in CD11c+ dendritic cells was 
also recorded, and these cells showed expression of CD80, CD86 
and CD103, denoting their maturation status43 (Fig. 3e,f). Thus, 
CD47 blockade enhances phagocytosis of cancer cells by both mac-
rophages and dendritic cells, activating innate immune systems.
Immunotherapeutic gel for inhibition of tumour recurrence
To validate the therapeutic effects of aCD47@CaCO3@fibrin, we 
used an incomplete tumour resection model. The in situ formed 
fibrin gels containing IgG@CaCO3, aCD47 or aCD47@CaCO3 (1 mg 
CaCO3 per mouse; 50 μ g aCD47 per mouse) were sprayed into the 
tumour resection cavity. Tumour growth was then monitored by 
bioluminescence signals from B16F10 cancer cells (Fig. 4a). Mice 
treated with the aCD47@CaCO3@fibrin showed improved con-
trol of tumour regrowth as four out of eight mice had no detect-
able tumour (Fig. 4b,c). Fifty per cent of the mice after aCD47@
CaCO3@fibrin treatment survived for at least 60 days (Fig. 4d), 
and the body weights of mice were not impacted by the treatment 
(Fig. 4e). Moreover, histology analysis of major organs collected 
from mice 30 days after aCD47@CaCO3@fibrin treatment, together 
with the complete blood panel test and serum biochemistry assay 
conducted at 1, 7 and 14 days after treatment, indicated that local 
delivery of aCD47 did not induce significant side effects to mice 
(Supplementary Figs. 13 and 14).
Residual tumours were harvested and analysed using flow 
cytometry and immunofluorescence staining 5 days after surgery. 
The proportion of both M1- and M2-type macrophages in the resid-
ual tumour was increased after aCD47 blockade, together with an 
increased polarization of M1-phenotype TAMs after CaCO3 treat-
ment (Fig. 5a and Supplementary Fig. 15). Similarly, the absolute 
number of TILs (CD3+ cells) was increased in the residual tumour 
after aCD47@CaCO3@fibrin treatment (Fig. 5b). Furthermore, 
the percentage of CD8+ T cells was significantly increased in the 
tumours after aCD47@CaCO3@fibrin treatment as compared to 
controls (Fig. 5b,c). Proliferation of CD4+ T cells was also increased, 
while the percentage of Tregs (CD4+Foxp3+ T cells) was decreased 
(Fig. 5d and Supplementary Fig. 16). Immunofluorescence stain-
ing visually indicated the marked increase in macrophages and 
CD8+ T cells in the residual tumours after aCD47@CaCO3@fibrin 
therapy (Fig. 5e and Supplementary Fig. 17). Secretion of cytokines 
including IFN-γ , IL-6 and IL-12p70 further confirmed the effective 
innate and adaptive immune responses induced by aCD47@
CaCO3@fibrin treatment (Fig. 5f).
Immunotherapeutic gel for treating distant tumours
With confirmation that aCD47@CaCO3@fibrin activates locally 
innate and adaptive immunity, we investigated whether local 
treatment with aCD47@CaCO3@fibrin triggers systemic immune 
responses. B16F10 cancer cells were inoculated in the opposite 
flank of the primary tumour to mimic tumour metastasis. Primary 
tumours were then partially resected, and fibrin gel containing 
aCD47@CaCO3 nanoparticles (1 mg CaCO3 per mouse; 50 μ g 
aCD47 per mouse) was sprayed into the tumour resection cavity 
(Fig. 6a). Local tumour recurrence was inhibited by aCD47@
CaCO3@fibrin treatment, and tumour growth at the opposite site 
was also reduced (Fig. 6b-d). Consistent with these results, the 
numbers of M1-like TAMs and CD103+ dendritic cells were signif-
icantly increased in tumours sprayed with aCD47@CaCO3@fibrin 
(Fig. 6e,f), and CD8+ T cells were increased in both treated and dis-
tant tumours (Fig. 6g and Supplementary Fig. 18). The increased 
CD8+ T cells in the distant tumour can be attributed to local cross-
presentation of tumour antigens by macrophages and dendritic 
cells that trigger systemic antitumour immunity. Activation of the 
immune system was further confirmed by the peritumoral injec-
tion of aCD47@CaCO3@fibrin by a dual-syringe administration 
method (Supplementary Fig. 19). aCD47@CaCO3@fibrin-medi-
ated treatment effectively inhibited the growth of both local and 
distant tumours.
We further evaluated the combination efficacy of anti-
PD-1 (aPD1) and aCD47 co-delivered by the sprayed gel3,44–47. 
Similarly, the primary tumours were partially resected and the 
surgical sites were sprayed with different fibrin gels containing 
aCD47@CaCO3 nanoparticles (50 μ g aCD47 per mouse), aPD1@
CaCO3 nanoparticles (50 μ g aPD1 per mouse) or aCD47&aPD1@
CaCO3 nanoparticles (25 μ g aCD47 per mouse; 25 μ g aPD1 per 
mouse). Encouragingly, a synergistic effect was achieved with 
aCD47&aPD1@CaCO3@fibrin treatment in inhibiting tumour 
recurrence after surgery and distant tumours, as shown in the 
bioluminescence imaging and growth profiles of local and distant 
tumours (Supplementary Fig. 20).
Conclusion
In summary, we have developed a simple post-surgical cancer 
immunotherapy strategy by spraying in situ formed therapeutic 
gel at the tumour resection site, which could facilitate reversal 
of the immunosuppressive TME and induce systemic immuno-
logical responses that inhibit both local recurrence and systemic 
development. CaCO3 nanoparticles embedded in the gel matrix 
could help release therapeutics in a controlled manner and 
modulate the acidic and inflamed tumour resection environ-
ment by scavenging H+, thereby promoting antitumour immune 
responses. Furthermore, the locally released aCD47 from CaCO3 
nanoparticles blocked the ‘don’t eat me’ signal associated with 
cancer cells, allowing cancer cell removal by macrophages. CD47 
blockade also triggered the T cell mediated destruction of cancer 
cells due to the enhanced presentation of tumour-specific anti-
gen by macrophages and dendritic cells. These results encour-
age the potential clinical translation of this method upon tumour 
resection. To this end, future evaluations in large animal mod-
els are expected to optimize drug dosage, particle amount and 
treatment frequency.
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Methods
Materials, cell lines and animals. All chemicals were purchased from Sigma-
Aldrich and used without any purification. Murine thrombin and fibrinogen were 
purchased from Molecular Innovations. aCD47 and aPD1 were purchased from 
Biolegend (cat. no. 127518, Clone, miap301; cat. no. 135233, Clone, 29F.1A12). 
The murine melanoma cell line B16F10 was purchased from UNC tissue culture 
facility. B16F10-luc cells were obtained from L. Huang at UNC. Cells were cultured 
in Dulbecco’s modified Eagle medium (Gibco, Invitrogen) containing 10% fetal 
bovine serum (Invitrogen) and 100 U ml−1 penicillin (Invitrogen) in an incubator 
at 37 °C in 5% CO2. Female C57BL/6 mice (6–10 weeks) were purchased from 
the Jackson Lab. All mouse studies were carried out following protocols approved 
by the Institutional Animal Care and Use Committee at the University of North 
Carolina at Chapel Hill and North Carolina State University and complied with all 
relevant ethical regulations.
Preparation and characterization of aCD47@CaCO3. aCD47@CaCO3 
nanoparticles were prepared by chemical precipitation. Typically, 1 ml of Tris-HCl 
buffer (1 mM, pH 7.6) containing 100 mM CaCl2 was mixed with 1 ml HEPES 
saline buffer (50 mM, pH 7.1, NaCl 140 mM) containing 100 μ g aCD47, 10 mg 
PEG-b-P(Glu) block copolymers (synthesized as previously described48) and 
10 mM Na2CO3. The mixture was stirred for 12 h at 4 °C. Excess ions, copolymers 
and antibodies were removed by centrifugation at 14,800 r.p.m. for 5 min. The 
size distribution was measured by dynamic light scattering and morphology was 
evaluated by TEM (JEOL 2000FX). The elemental analysis of aCD47@CaCO3 
(aCD47 was chelated gadolinium as previously described49) was characterized 
using analytical TEM (Titan). The amount of aCD47 encapsulated in CaCO3 was 
measured by enzyme-linked immunosorbent assay (ELISA) (rat IgG total ELISA 
kit, eBioscience, cat. no. 88-50490-22). The encapsulation efficiency (EE) and 
loading capacity (LC) of CaCO3 nanoparticles were calculated using the following 
formula: EE = (A − B)/A and LC = (A − B)/C, where A is the feed amount of 
antibody, B is the free non-entrapped antibody and C is the total weight of particles.
Formation and characterization of aCD47@CaCO3@fibrin. Fibrin gels were 
obtained by spraying equal volumes of fibrinogen (10 mg ml−1) containing 
aCD47@CaCO3 and thrombin (10 NIH U ml−1). For the control group without 
CaCO3 nanoparticles, CaCl2 was incorporated with the same amount of free 
Ca2+ compared with the solution with CaCO3 nanoparticles. The morphology of 
aCD47@CaCO3@fibrin was characterized by cryo-SEM (JEOL 7600F, Gatan Alto). 
Encapsulation of aCD47@CaCO3 in fibrin was further characterized by a confocal 
microscope (Zeiss LSM 710).
Release of aCD47 in vitro. The release of aCD47 was studied at 37 °C in PBS at 
various pH values (pH 6.5 and 7.4). Released aCD47 was measured using a rat IgG 
total ELISA kit.
Release of aCD47 in vivo. To study the in vivo release of aCD47, Cy5.5-labelled free 
aCD47 or aCD47@CaCO3 dispersed in PBS was injected at the tumour resection site. 
For gel administration, equal volumes of fibrinogen solution (10 mg ml−1) containing 
aCD47@CaCO3 with the same dose of aCD47 (50 μ g per mouse) and thrombin 
solution (10 NIH U ml−1) were sprayed at the tumour resection site. Fluorescence 
imaging was monitored by an IVIS Spectrum imaging system (Perkin Elmer). 
To investigate whether the antibody was released from the nanoparticles or still 
encapsulated in the nanoparticles, we studied intratumoral antibody release behaviour 
using FITC-labelled CaCO3 nanoparticles. Tumours were collected at different time 
points after spraying the hydrogel, and the frozen tumour sections were stained with 
DAPI and rhodamine (TRITC)-conjugated donkey anti-rat IgG antibody.
In vitro phagocytosis assay. Bone-marrow-derived macrophage cells (BMDMs) 
were prepared as previously described50, stained with CellTracker Green (C7025, 
Thermo-Fisher Scientific), and cancer cells were stained with CellTracker DeepRed 
(C34565, Thermo-Fisher Scientific). Cancer cells (4 × 105) pre-blocked with IgG or 
aCD47 were co-cultured with macrophages (1 × 105) in serum-free medium. After 
incubation for 2 h at 37 °C, phagocytosis was studied by confocal microscopy (Zeiss 
LSM 710) and CytoFLEX flow cytometry (Beckman).
In vivo tumour models and treatment. To study the therapeutic effects of aCD47@
CaCO3@fibrin, 1 × 106 fLuc-B16F10 cells were transplanted into the right flanks 
of mice. Ten days later, mice were randomly divided into five groups (n = 6–8) 
and tumours were resected, leaving ~1% residual tumour to mimic residual micro 
tumours after surgery. Briefly, mice were anaesthetized in an induction chamber 
using isoflurane (up to 5% for induction; 1–3% for maintenance), and anaesthesia 
was maintained via a nose cone. Sterile instruments were used to remove ~99% 
of the tumour. Immediately after surgery, fibrin gels with different formulations, 
including fibrin, IgG@CaCO3@fibrin, aCD47@fibrin and aCD47@CaCO3@fibrin 
with calculated dosages of antibody, were sprayed on the surgical tumour bed 
by a dual-cartridge sprayer. The wound was then closed by an Autoclip wound 
clip system. For the distant tumour model, 7 days after 1 × 106 fLuc-B16F10 were 
transplanted into the right flank of mice, a second tumour as the distant tumour 
(1 × 106 fLuc-B16F10) was inoculated into the left flank of each mouse. Three days 
later, tumours in the right flank were partially resected and the immune therapeutic 
gel was sprayed on the surgical tumour bed. The tumour size was measured and 
calculated according to the following formula: width2 × length × 0.5. The tumour 
was also observed using an in vivo bioluminescence imaging system. Ten minutes 
after intraperitoneal injection of d-luciferin (Thermo Scientific Pierce) in DPBS 
(15 mg ml−1) into each mouse at a dose of 10 µ l g−1, mice were imaged using an 
IVIS Spectrum Imaging System (Perkin Elmer) for 5 min. Regions of interest 
were quantified as the average radiance (photons s−1 cm−2 sr−1) using Living Image 
software. Animals were euthanized when showing signs of imperfect health or 
when the size of their tumours exceeded 1.5 cm3.
Cytokine detection. The intratumour and plasma levels of IL-10 (Invitrogen, cat. 
no. BMS215-2), IL-12p70 (Invitrogen, cat. no. BMS6004TEN), IL-6 (Invitrogen, 
cat. no. BMS603-2), IFN-γ (Invitrogen, cat. no. BMS606INST) and TNF-α 
(Invitrogen, cat. no. BMS607-3) were measured with ELISA kits according to the 
manufacturer’s instructions. For detection of the local (tumour) concentration of 
cytokines, 5 days after spraying the fibrin gels, the tumour tissue was harvested 
and then homogenized in cold PBS buffer in the presence of digestive enzymes, 
forming single cell suspensions. For the plasma levels, serum samples were isolated 
from mice after different treatments and diluted for analysis.
Flow cytometry. Tumours collected from mice were divided into small pieces and 
homogenized in cold staining buffer to form single cell suspensions in the presence 
of digestive enzyme. Cells were stained with fluorescence-labelled antibodies 
CD45 (Biolegend, cat. no. 103108, clone 30-F11), CD11b (Biolegend, cat. no. 
101208, clone M1/70), CD206 (Biolegend, cat. no. 141716, clone C068C2), F4/80 
(Biolegend, cat. no. 123116, clone BM8), CD80 (Biolegend, cat. no. 104722, clone 
16-10A1), Gr-1 (Biolegend, cat. no. 108412, clone RB6-8C5), CD3 (Biolegend, 
cat. no. 100204, clone 17A2), CD4 (Biolegend, cat. no. 100412, clone GK1.5), CD8 
(Biolegend, cat. no. 140408, clone 53–5.8), Foxp3 (Biolegend, cat. no. 126404, 
clone MF-14), CD11c (Biolegend, cat. no. 117310, clone N418), CD86 (Biolegend, 
cat. no. 105008, clone GL-1), CD103 (Biolegend, cat. no. 121406, clone 2E7), 
Ly6C (Biolegend, cat. no. 128016, clone HK1.4) and Ly6G (Biolegend, cat. no. 
127608, clone 1A8) following the manufacturer's instructions. All antibodies were 
diluted 200 times. The stained cells were measured on a CytoFLEX flow cytometer 
(Beckman) and analysed by FlowJo software (version 10.0.7, TreeStar). The 
numbers presented in the flow cytometry analysis images are percentage based.
Immunofluorescence staining. Tumours were collected from the mice and snap-
frozen in optimal cutting temperature medium. Tumour sections were cut using a 
cryotome, mounted on slides and stained with different primary antibodies: CD4 
(Abcam, cat. no. ab183685), CD8 (Abcam, cat. no. ab22378) and F4/80 (Abcam, 
cat. no. ab100790) overnight at 4 °C following the manufacturer's instructions. 
Following the addition of fluorescently labelled secondary antibodies (goat anti-rat 
IgG (H + L; Thermo Fisher Scientific, cat. no. A18866) and goat anti-rabbit IgG 
(H + L; Thermo Fisher Scientific, cat. no. A32733)), the slides were analysed with a 
confocal microscope (Zeiss LSM 710). All antibodies used in the experiments were 
diluted 200 times.
Western blotting. Equal amounts of protein (measured using a bicinchoninic acid 
protein assay kit, BCA) were mixed with an equal volume of 2× Laemmli buffer 
and boiled at 95 °C for 5 min. After gel electrophoresis and protein transformation, 
anti-HIF1-α (28b) antibody at a dilution of 1:1,000 (Santa Cruz, cat. no. sc-13515) 
and anti-β -actin antibody (Abcam, cat. no. ab8226) at a 1:5,000 dilution were used 
as primary antibodies. The secondary antibody used for these blots was a goat anti-
mouse antibody (Novus Biologicals, cat. no. NBP1-75151).
Statistical analysis. All results are presented as the mean ± standard error of the 
mean (s.e.m.), as indicated. Tukey post-hoc tests and one-way ANOVA were used for 
multiple comparisons (when more than two groups were compared), and Student’s t-
test was used for two-group comparisons. Survival benefit was determined using a log-
rank test. All statistical analyses were carried out with Prism software package (PRISM 
5.0; GraphPad Software, 2007). The threshold for statistical significance was P < 0.05.
Reporting summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The data that support the plots within this paper and other findings of this study 
are available from the corresponding author upon reasonable request.
references
 48. Nishiyama, N. et al. Novel cisplatin-incorporated polymeric micelles can
eradicate solid tumors in mice. Cancer Res. 63, 8977–8983 (2003).
 49. Chen, Q. et al. An albumin-based theranostic nano-agent for dual-modal
imaging guided photothermal therapy to inhibit lymphatic metastasis of
cancer post surgery. Biomaterials 35, 9355–9362 (2014).
 50. Lee, E. J. et al. Nanocage‐therapeutics prevailing phagocytosis and immunogenic
cell death awakens immunity against cancer. Adv. Mater. 30, 1705581 (2018).
